LaunchPort’s Novel Microdevices Lands Important Funding from Carb-X Global Partnership
- No Comments
Novel Microdevices (https://noveldx.com/) was awarded up to $13.8 million from CARB-X (https://carb-x.org/) for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections such as Chlamydia trachomatis and Neisseria gonorrhoeae. Novel’s new device would diagnose infections in about 25 minutes from a vaginal swab or urine sample, and detect antibiotic-resistant bacteria, including those resistant to ciprofloxacin and 3rd generation cephalosporins, the only antibiotics that are still effective as treatments for most strains of the gonorrhoeae bacteria.
Novel established residency at LaunchPort’s City Garage location in Port Covington, Baltimore, earlier this year to develop their GMP processes for device and cartridge production. The Company operates engineering modules and cleanroom processes at The LaunchPort and lab operations at Baltimore’s IMET Research Center on the Inner Harbor.